Having led many operational improvement initiatives and programs, I’ve learned resistance to change comes in different forms. These forms are many and varied, ranging from the overt, such as, “I don’t think this will work and am not willing to spend time on it” to the more covert, for example “road-blocking” as in “I need much more information before I can get on board.” The key to dealing with this resistance usually lies in first recognizing it as normal, second recognizing the type of resistance being displayed, and third determining an appropriate approach to dealing with it. As we know, more than a few books and articles have been written on the topic.
Archive for September, 2010
Many Biotech and Pharma companies at various stages of maturity struggle with an accurate tracking mechanism for managing all of their samples. Similar to commercial and clinical inventory (management / tracking / visibility), SAMPLE VISIBILITY is also a significant issue for Life Science companies! There are several considerations, for example:
• Legal: e.g. when a patient withdraws from a study and wants their specimens withdrawn and/or destroyed.
• Regulatory: such as how long samples are to be kept in storage.
• Logistics: packaging, labeling, and shipping conditions.
• Cost: such as absorbing expensive long term storage.
Filed under the “boring, but potentially very important” header, the Supreme Court earlier this summer reaffirmed a broad definition of patentability for methods that are very important to the biotech and life sciences industry.